Deuterated drugs

Journal of Psychosocial Nursing and Mental Health Services

Volumn 53, Issue 9, 2015, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTERIUM; DEXTROMETHORPHAN; PAROXETINE; PRESCRIPTION DRUG; TETRABENAZINE;

CHEMISTRY; HUMAN;

DEUTERIUM; DEXTROMETHORPHAN; HUMANS; PAROXETINE; PRESCRIPTION DRUGS; TETRABENAZINE;

EID: 84947061924     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20150821-55     Document Type: Article

References (14)

1. Belleau, B., Burba, J., Pindell, M., & Reiffenstein, J. (1961). Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science, 133, 102-104. doi:10.1126/science.133.3446.102
2. Brooks, B.R., Thisted, R.A., Appel, S.H., Bradley, W.G., Olney, R.K., Berg, J.E., Smith, R.A. (2004). Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology, 63, 1364-1370
3. Harbeson, S.L., & Tung, R.D. (2014). Deuterium medicinal chemistry: A new approach to drug discovery and development. Medchem News, 2, 8-22
4. Howland, R.H. (2006). Personalized drug therapy with pharmacogenetics. Part 1: Pharmacokinetics. Journal of Psychosocial Nursing and Mental Health Services, 44(1), 13-16
5. Katsnelson, A. (2013). Heavy drugs draw heavy interest from pharma backers. Nature Medicine, 19, 656. doi:10.1038/nm0613-656
6. Kerrigan, S. (2009). Deuterated therapeutics: Forensic toxicology consequences. Journal of Analytical Toxicology, 33, 393-394
7. Lauterbach, E.C. (2012). An extension of hypotheses regarding rapid-acting treatment-refractory and conventional antidepressant activity of dextromethorphan and dextrorphan. Medical Hypotheses, 78, 693-702. doi:10.1016/j.mehy.2012.02.012
8. Ondo, W.G., Hanna, P.A., & Jankovic, J. (1999). Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. American Journal of Psychiatry, 156, 1279-1281
9. Pace, N.R. (2001). The universal nature of biochemistry. Proceedings of the National Academy of Sciences of the United States of America, 98, 805-808. doi:10.1073/pnas.98.3.805
10. Pope, L.E., Khalil, M.H., Berg, J.E., Stiles, M., Yakatan, G.J., & Sellers, E.M. (2004). Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. Journal of Clinical Pharmacology, 44, 1132-1142. doi:10.1177/0091270004269521
11. Shaibani, A.I., Pope, L.E., Thisted, R., & Hepner, A. (2012). Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: A double-blind placebo-controlled multicenter study. Pain Medicine, 13, 243-254. doi:10.1111/j.1526-4637.2011.01316.x
12. Uttamsingh, V., Gallegos, R., Liu, J.F., Harbeson, S.L., Bridson, G.W., Cheng, C., Tung, R. (2015). Altering metabolic profiles of drugs by precision deuteration: Reducing mechanism-based inhibition of CYP2D6 by paroxetine. Journal of Pharmacology and Experimental Therapeutics, 354, 43-54. doi:10.1124/jpet.115.223768
13. Yang, L.P.H., & Deeks, E.D. (2015). Dextromethorphan/quinidine: A review of its use in adults with pseudobulbar affect. Drugs, 75, 83-90
14. Zhang, Y., Britto, M.R., Valderhaug, K.L., Wedlund, P.J., & Smith, R.A. (1992). Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clinical Pharmacology and Therapeutics, 51, 647-655